-
1.发明申请Pharmaceutical Formulation containing an HMG-COA Reductase Inhibitor and method for the preparation thereof 审中-公开含有HMG-COA还原酶抑制剂的药物制剂及其制备方法公开(公告)号：US20100196469A1
公开(公告)日：2010-08-05
申请号：US12663513
申请日：2007-06-25
IPC分类号： A61K9/48 , A61K31/40 , A61K31/405 , A61P9/10 , A61K9/52
CPC分类号： A61K9/2009 , A61K31/40
摘要： The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Atorvastatin or Fluvastatin or salts thereof, in combination with colloidal clay such as Attapulgite, and a process for the preparation thereof by direct compression.
摘要翻译： 本发明涉及固体剂型的制剂，其包含治疗有效量的HMG-CoA还原酶抑制剂，特别是阿托伐他汀或氟伐他汀或其盐，与胶态粘土如绿坡缕石组合，以及其制备方法 直接压缩。
-
2.发明申请公开(公告)号：US20110033538A1
公开(公告)日：2011-02-10
申请号：US12739475
申请日：2007-10-16
申请人： Evangelos Karavas , Efthimios Koutris , Dimitrios Bikiaris , Vicky Samara , Ioanna Koutri , Eleni Stathaki
发明人： Evangelos Karavas , Efthimios Koutris , Dimitrios Bikiaris , Vicky Samara , Ioanna Koutri , Eleni Stathaki
IPC分类号： A61K31/4015 , A61K9/28 , A61P25/08
CPC分类号： A61K31/4015 , A61K9/2009 , A61K9/2027 , A61K9/2054 , A61K9/2095
摘要： The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Dibasic Calcium Phosphate, and additional pharmaceutical excipients, and a process for the preparation thereof by wet granulation.
摘要翻译： 本发明涉及一种固体剂型的药物制剂，其包含治疗有效量的吡咯烷酮抗惊厥剂，特别是左乙拉西坦或其药学上可接受的盐或衍生物，与有效稀释剂如磷酸氢二钙和 另外的药物赋形剂，以及通过湿法制粒制备方法。
-
3.发明授权公开(公告)号：US08187635B2
公开(公告)日：2012-05-29
申请号：US12739475
申请日：2007-10-16
申请人： Evangelos Karavas , Efthimios Koutris , Dimitrios Bikiaris , Vicky Samara , Ioanna Koutri , Eleni Stathaki
发明人： Evangelos Karavas , Efthimios Koutris , Dimitrios Bikiaris , Vicky Samara , Ioanna Koutri , Eleni Stathaki
IPC分类号： A61K9/28
CPC分类号： A61K31/4015 , A61K9/2009 , A61K9/2027 , A61K9/2054 , A61K9/2095
摘要： The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Dibasic Calcium Phosphate, and additional pharmaceutical excipients, and a process for the preparation thereof by wet granulation.
摘要翻译： 本发明涉及一种固体剂型的药物制剂，其包含治疗有效量的吡咯烷酮抗惊厥剂，特别是左乙拉西坦或其药学上可接受的盐或衍生物，与有效稀释剂如磷酸氢二钙和 另外的药物赋形剂，以及通过湿法制粒制备方法。
-
4.发明申请Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof 审中-公开包含选择性雌激素受体调节剂的改进的药物组合物及其制备方法公开(公告)号：US20110065751A1
公开(公告)日：2011-03-17
申请号：US12739545
申请日：2007-10-16
申请人： Evangelos Karavas , Efthimios Koutris , Dimitrios Bikiaris , Vicky Samara , Anastasia Kalaskani , Eleni Stathaki
发明人： Evangelos Karavas , Efthimios Koutris , Dimitrios Bikiaris , Vicky Samara , Anastasia Kalaskani , Eleni Stathaki
IPC分类号： A61K31/4535 , A61P19/10
CPC分类号： A61K31/4535 , A61K9/2009 , A61K9/2054 , A61K9/2059 , A61K9/2813 , A61K9/2866
摘要： The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a selective estrogen receptor modulator, and especially Raloxifene or a pharmaceutical acceptable salt thereof, in combination with a super disintegrant such as Primojel, and a process for the preparation thereof by wet granulation.
摘要翻译： 本发明涉及固体剂型的药物制剂，其包含治疗有效量的选择性雌激素受体调节剂，特别是雷洛昔芬或其药学上可接受的盐与超级崩解剂如Primojel的组合，以及制备方法 通过湿法制粒。
-
5.发明申请公开(公告)号：US20100297225A1
公开(公告)日：2010-11-25
申请号：US12747211
申请日：2007-12-20
IPC分类号： A61K9/52 , A61K31/137 , A61P13/00
CPC分类号： A61K9/4808 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K31/00
摘要： The present invention relates to improved sustained release dosage forms such as tablets and capsules, and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an antimuscarinic agent, such as Tolterodine or pharmaceutical acceptable salt, derivative, prodrug and metabolite thereof in combination with a wetting agent, such as Sodium Docusate to improve the release of the active ingredient and a method for the preparation thereof.
摘要翻译： 本发明涉及改进的缓释剂型，例如片剂和胶囊，特别涉及用于口服给药的药物制剂，其包含治疗有效量的抗毒蕈碱剂，例如托特罗定或其药学上可接受的盐，衍生物，前药和代谢物 与润湿剂如多库酯钠组合以改善活性成分的释放及其制备方法。
-
6.发明申请公开(公告)号：US20140235656A1
公开(公告)日：2014-08-21
申请号：US14353074
申请日：2011-10-25
IPC分类号： A61K9/00 , A61K9/20 , A61K31/522
CPC分类号： A61K9/006 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2095 , A61K31/138 , A61K31/522 , A61K2300/00
摘要： The present invention relates to a stable pharmaceutical composition for sublingual administration comprising a therapeutically effective quantity of an antihistamine agent, in particular Dimenhydnnate and a process for the preparation thereof.
摘要翻译： 本发明涉及用于舌下施用的稳定的药物组合物，其包含治疗有效量的抗组胺剂，特别是二氢萘酸酯及其制备方法。
-
公开(公告)号：US09675551B2
公开(公告)日：2017-06-13
申请号：US14353074
申请日：2011-10-25
IPC分类号： A61K9/00 , A61K9/20 , A61K31/522 , A61K31/138
CPC分类号： A61K9/006 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2095 , A61K31/138 , A61K31/522 , A61K2300/00
摘要： The present invention relates to a stable pharmaceutical composition for sublingual administration comprising a therapeutically effective quantity of an antihistamine agent, in particular Dimenhydnnate and a process for the preparation thereof.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.017 秒)
